Curza

United States
Salt Lake City, Utah, United States, 84108

Company profile

Curza company profile

Curza is a small-molecule therapeutics company that has developed several structurally distinct classes of proprietary drugs focused on infectious diseases and oncology. Curza’s lead program is a new class of broad spectrum antibiotics, focused on ESKAPE pathogens and drug-resistant Gram-negative bacteria. Inspired by a natural product, this class targets an unexploited binding site of the bacterial ribosome. With ever increasing reports of resistance to frontline therapies addressing Gram-negative bacteria, there is a critical need for new therapies and new therapies that work in new ways. However, very little can be found in the development pipeline. As a result, Curza’s compounds are addressing a major unmet medical need.

Business identity

Phone number
(617) 575-2202
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$1M-$10M
Founded
2013-01-01, Year

Headquarters

Postal code
84108
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding rounds
8
Total equity funding
$10.3M
Last funding
Series Unknown / $5.3M / 2019-07-25
Last equity funding
Series Unknown / $5.3M
Investors
9
Lead investors
9
Founders
1
Articles
4

Founders and investors

Founders

Robert Mooney

Lead investors

American Chemical SocietyCARB-XClarke Capital PartnersNational Institute of Allergy and Infectious DiseasesNational Institute of General Medical ScienceRepair Impact FundSmall Business Innovation ResearchU.S. Department of DefenseU.S. Department of Veteran Affairs

Investors

CARB-XNational Institute of Allergy and Infectious DiseasesNational Institute of General Medical ScienceRepair Impact FundU.S. Department of Defense